RxDoctor Payments Data

Gabriel Aguilar, MD

Ophthalmology · San Francisco, CANPI 1366544371

Payments from drug & device makers

$1,596in general payments, 2019–2025

Across 67 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$360
  • Alcon$197
  • Oyster Point Pharma, Inc.$191
  • Aerie Pharmaceuticals, Inc.$136
  • Amgen$128
  • Sun Pharmaceutical Industries Inc.$121
  • plus $464 from 12 others

What the payments were for

  • Food & beverage$1,596100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,596 in reported general payments places this provider in the 50th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$286,616
Medicare patients
755
Services billed
2,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod107$44,576
LumiganBimatoprost47$30,661
RocklatanNetarsudil Mesylat/Latanoprost16$9,839
Prednisolone Acetate146$6,800
Brinzolamide20$5,010
Ketorolac Tromethamine146$4,013
Latanoprost281$3,579
XalatanLatanoprost12$3,119
Ofloxacin144$2,225
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat152$1,854
Brimonidine Tartrate33$1,181
Methazolamide139$1,103
Dorzolamide Hcl52$763
Timolol Maleate32$257
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha21$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$67$44,576107 claims
AbbVieLumigan$360$30,66147 claims
Aerie Pharmaceuticals, Inc.Rocklatan$136$9,83916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →